NCT07117084

Brief Summary

Despite the widespread use of stents, previous studies have shown that stent implantation mainly relieves symptoms but may not significantly improve long-term outcomes in patients with stable coronary artery disease. Identifying the types of plaques that are most likely to benefit from stenting is essential for improving personalized treatment. This study explores whether coronary computed tomography angiography (CCTA)-derived imaging biomarkers of coronary plaques are associated with increased risk of adverse outcomes after percutaneous coronary intervention (PCI). Around 2,000 patients who underwent CCTA followed by stent placement were included. Advanced software was used to quantify plaque inflammation and composition. Findings from this research may help guide personalized treatment strategies in patients undergoing PCI.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 5, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 12, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

August 12, 2025

Status Verified

August 1, 2025

Enrollment Period

4 years

First QC Date

August 5, 2025

Last Update Submit

August 5, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Major adverse cardiovascular events (MACE)

    Composite of cardiovascular death, non-fatal myocardial infarction, repeat revascularization, and hospitalization for unstable angina.

    From the date of PCI until December 2024 (minimum 2-year follow-up)

Study Arms (1)

CCTA-PCI Cohort

Patients who underwent coronary CT angiography followed by PCI within 30 days.

Diagnostic Test: CCTA-derived Plaque Quantification

Interventions

Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.

CCTA-PCI Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who underwent clinically indicated PCI within 30 days after coronary CT angiography.

You may qualify if:

  • patients aged 18 years or older;
  • patients who underwent clinically indicated PCI within 30 days following CCTA;
  • CCTA demonstrating the presence of coronary atherosclerotic plaque.

You may not qualify if:

  • patients whose PCI within 30 days after CCTA was performed on an emergency basis;
  • elevated cardiac troponin levels within the 3 months preceding PCI;
  • inadequate CCTA image quality;
  • balloon-only or mixed stent/balloon PCI strategies;
  • PCI for non-atherosclerotic lesions (e.g., in-stent restenosis, spontaneous coronary dissection);
  • history of coronary artery bypass grafting;
  • heart failure;
  • non-ischemic cardiomyopathy;
  • significant valvular heart disease;
  • refractory hypertension;
  • persistent atrial fibrillation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100037, China

Location

Tai'an Central Hospital

Tai’an, Shandong, 271000, China

Location

Weifang People's Hospital

Weifang, Shandong, 261000, China

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Bin Lu, MD

    Chinese Academy of Medical Sciences, Fuwai Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 5, 2025

First Posted

August 12, 2025

Study Start

January 1, 2021

Primary Completion

December 31, 2024

Study Completion

December 1, 2025

Last Updated

August 12, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to institutional data privacy policies and lack of data-sharing agreements.

Locations